Investor portfolios

Investor profile

Delin Ventures

Venture firm investing in early-stage life sciences companies. Investor in IMMvention Therapeutix (Durham).

Venture fund

London, UK

Directory portfolio

Companies connected here

1

Latest company funding first, including rounds involving other investors. Unknown dates last.

I
IMMvention Therapeutix
Latest company funding · Dec 23, 2022
Preclinical biotech developing oral small-molecule BACH1 inhibitors for sickle cell disease and other chronic conditions, with its systemic program licensed to Novo Nordisk.

Portfolio coverage reflects public company-investor links tracked in this directory and may not represent the investor's full portfolio.